JAK2 and cancer: To this end, we first used siRNA to deplete Aurora A, JAK2 or Aurora A + JAK2 in 8 human cancer cell lines from different lineages; three from breast (MDA-MB-468, MDA-MB-231 and MCF7), two from lung (A549 and H460), two from colon (HCT116 and HT29) and one from prostate (DU145); and determined the effects of these depletions on anchorage-dependent cell proliferation by MTT assays as described under Materials and Methods.